Q3 2023 Financial Highlights

- Q3 2023 Revenue and Adjusted EBITDA Overview Significant year-over-year improvement in Revenue, Flight Profit, and Adjusted EBITDA Three Months Ended September 30, ($ in millions) Passenger Revenue 2022 2023 %A vs 2022 $25.5 $38.0 Medical Revenue 20.2 33.4 Total Revenue $45.7 $71.4 49.0% 65.4% 56.3% Passenger Flight Profit $6.1 $9.4 54.4% Medical Flight Profit 3.2 6.2 94.5% Total Flight Profit $9.3 $15.6 68.1% Passenger Flight Margin 23.9% 24.8% Medical Flight Margin 15.7% 18.4% nm nm Total Flight Margin 20.3% 21.8% nm Passenger Segment Adj. EBITDA $1.5 $2.8 Medical Segment Adj. EBITDA 1.5 3.3 Total Segment Adjusted EBITDA $3.0 $6.1 88.5% 124.0% 106.4% Passenger Segment Adj. EBITDA Margin 5.8% 7.3% nm Medical Segment Adj. EBITDA Margin 7.4% 10.0% nm Total Segment Adj. EBITDA Margin 6.5% 8.6% nm Unallocated corporate and software (7.5) (5.3) 29.0% expense Total Adjusted EBITDA ($4.5) $0.8 Total Adjusted EBITDA Margin (9.9%) 1.1% Note: Definition of all non-GAAP numbers and reconciliation to GAAP numbers are provided in the Appendix of this presentation BLADE Passenger revenue growth driven by (i) acquisition in Europe, (ii) strong utilization and pricing advancements in Blade Airport, (iii) growth across other Short Distance business lines, and (iv) higher Jet charter volumes Medical revenue growth driven by the addition of new transplant center clients, growth within existing clients, and strong market growth Improvement in Passenger Flight Margin attributable to (i) contribution from Blade Europe, (ii) strong utilization and pricing advancements in Blade Airport, and (iii) improved growth and profitability across other Short Distance business lines Improvement in Medical Flight Margin attributable to increased use of dedicated aircraft, which results in lower costs and less repositioning Decrease in corporate expense attributable to cost actions taken across the business 24 24

View entire presentation